SEATTLE CHILDREN'S HOSPITAL
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
202
Trial Phases
6 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (184 trials with phase data)β’ Click on a phase to view related trials
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
- Conditions
- Solid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell CarcinomaLiposarcomaYolk Sac TumorRhabdomyosarcoma
- Interventions
- Biological: SC-CAR.GPC3xIL15.21 CAR T cells
- First Posted Date
- 2025-11-04
- Last Posted Date
- 2025-11-04
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT07224568
- Locations
- πΊπΈ
Fred Hutch Cancer Center, Seattle, Washington, United States
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Conditions
- Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid TumorYolk Sac TumorLiposarcomaRhabdomyosarcomaEmbryonal Sarcoma of LiverWilms TumorHepatocellular CarcinomaHepatoblastoma
- Interventions
- Biological: SC-CAR.GPC3xIL15.21 CAR T cells
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT07148050
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
Concussion Recovery and Support Program
- Conditions
- Brain ConcussionMild Traumatic Brain InjuryHeadache
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07097792
- Locations
- πΊπΈ
Seattle Children's Research Institute, Seattle, Washington, United States
πΊπΈUniversity of Washington, Seattle, Washington, United States
Feasibility and Acceptability of the Technology Based Enhanced Gender Support Platform Implementation With Parents
- Conditions
- ParentsUsability
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT07022392
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06936670
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
πΊπΈUniversity of Washington Medicine Diabetes Institute, Seattle, Washington, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 41
- Next
News
Blinatumomab Combination Therapy Wins Prestigious Trial of the Year Award for Pediatric Leukemia Breakthrough
The Children's Oncology Group AALL1731 trial received the David Sackett Trial of the Year Award for demonstrating that adding blinatumomab to chemotherapy reduces relapse risk by about two-thirds in children with B-cell acute lymphoblastic leukemia.
B7-H3 CAR T-Cell Therapy Shows Promise in Diffuse Intrinsic Pontine Glioma
A phase I clinical trial demonstrates the feasibility and tolerability of repeated intraventricular B7-H3 CAR T-cell infusions in children with DIPG.